Expired activity
Please go to the PowerPak
homepage and select a course.
FACULTY
Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Torrance, CA
Disclosures:
Consulting Fee (Paid to Institution): Bristol-Myers Squibb, Gilead, Janssen, Merck, Teva, ViiV
Contracted Research (Paid to Institution): Gilead, Merck, ViiV
Richard A. Elion, MD
Associate Clinical Professor of Medicine
George Washington University School of Medicine
Co-Director, DC Dept of Health STD Research Program
Washington, DC
Disclosures:
Consulting Fee: Gilead, ViiV
Speakers Bureau: Gilead, Janssen, Merck, ViiV
Advisor: Gilead, Merck, Viiv
Expert Witness: Gilead
External Reviewer:
Renslow Sherer, MD
Disclosures:
Consulting Fees: Gilead
Grant Support: Gilead, Janssen
Nurse Planners:
Barbara Turk, RN, MPH
Disclosures: No relevant financial relationships to disclose.
Henry Weinberger, RN, MSN
Disclosures: No relevant financial relationships to disclose.
Pharmacy Reviewer:
Jennifer Frederick, PharmD, BSCP
Disclosure: No relevant financial relationships to disclose.
The University of Chicago Pritzker School of Medicine and Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at The University of Chicago Pritzker School of Medicine and Vindico Medical Education, Office of Medical Affairs and Compliance.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center, and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, all CME/CNE/CPE providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of CME/CNE/CPE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME/CNE/CPE activity content over which the individual has control. Relationship information appears above.
Unlabeled and Investigational Usage:
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Accreditation:
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation:
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide 2.0 contact hours for nurses.
This program is acceptable for 2.0 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-9999-16-009-H02-P, effective 12/30/2016. This is an application-based activity and there is no fee to participation.
This enduring material is approved for 1 year from the date of original release, December 30, 2016 to December 29, 2017.
How to Participate in this Activity and Obtain CME/CNE/CPE Credit:
To participate in this CME/CNE/CPE activity, you must read the objectives, answer the pretest questions, complete two or more scenarios (6 total), take the CME/CNE/CPE posttest questions, and fill-in the evaluation. To receive credit, at least two simulation scenarios must be completed with a score of three or more stars (out of five stars). Completion of more scenarios will result in more available credit up the maximum amount for this activity. Upon receipt of the completed materials, The University of Chicago Pritzker School of Medicine will issue an AMA PRA Category 1 Credit(s)™ Certificate, Vindico Medical Education will issue a Learner-paced Contact Hours Certificate, or Vindico Medical Education will issue a Certificate of Pharmacy Credit.
Overview:
Highly effective antiretroviral therapy (ART) has transformed HIV from a rapidly deteriorating condition to a complex, chronic condition, with individuals now expecting to live a normal lifespan. With longer survival, patients will be exposed to antiretroviral agents for decades. Therefore, maximizing the safety and tolerability of therapies, as well as preventing resistance is a high priority. Significant progress has been made toward simplified, single-tablet regimens, optimizing the long-term safety and tolerability of therapy. Despite these advances, clinicians face challenges when selecting and maintaining therapy. In this interactive activity, expert faculty will use a case-based approach to discuss various aspects of HIV management, including optimal starting regimens for treatment-naïve patients, as well as the role of switching therapy in treatment-experienced patients. They also will integrate updated guideline recommendations and evidence from recent clinical trials to identify best practices in the management of HIV.
Target Audience:
The intended audience for this activity is infectious disease physicians, family physicians, primary care physicians, internal medicine physicians, nurses, pharmacists and other health care professionals involved in the treatment of patients with HIV.
Purpose/Learning Objectives:
Upon successful completion of this educational activity, physicians should be better able to:
- Implement initial HIV treatment strategies that reflect important patient characteristics, including age, medical work-up, comorbidities, and potential DDIs in accordance with evidence-based treatment guidelines.
- Review the impact of proper adherence to HIV therapy in preventing the emergence of resistance and optimizing treatment response.
- Use simplified HIV treatment regimens that reflect patient preference and optimize adherence in both the initial and post-failure settings.
- Examine the resistance profiles of available and emerging HIV treatment regimens.
- Identify virally-suppressed patients who may benefit from alteration to their HIV treatment.
- Utilize knowledge of effective HIV switching therapies and NRTI-sparing regimens when altering therapy in virally-suppressed patients.
Upon successful completion of this educational activity, nurses should be better able to:
- Review the impact of proper adherence to HIV therapy in preventing the emergence of resistance and optimizing treatment response.
- Examine the resistance profiles of available and emerging HIV treatment regimens.
- Identify virally-suppressed patients who may benefit from alteration to their HIV treatment.
Upon successful completion of this educational activity, pharmacists should be better able to:
- Implement initial HIV treatment strategies that reflect important patient characteristics, including age, medical work-up, comorbidities, and potential DDIs in accordance with evidence-based treatment guidelines.
- Review the impact of proper adherence to HIV therapy in preventing the emergence of resistance and optimizing treatment response.
- Use simplified HIV treatment regimens that reflect patient preference and optimize adherence in both the initial and post-failure settings.
- Examine the resistance profiles of available and emerging HIV treatment regimens.
- Identify virally-suppressed patients who may benefit from alteration to their HIV treatment.
- Utilize knowledge of effective HIV switching therapies and NRTI-sparing regimens when altering therapy in virally-suppressed patients.
Copyright Statement:
This CME/CNE/CPE activity is licensed to Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA. Copyright © 2016 Syandus Inc. and Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from Vindico Medical Education and Syandus Inc.
The material presented at or in any of The University of Chicago Pritzker School of Medicine and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of The University of Chicago Pritzker School of Medicine and Vindico Medical Education. Neither The University of Chicago Pritzker School of Medicine, Vindico Medical Education, the ACCME, the ANCC, the ACPE, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME/CNE/CPE Questions?
Contact us at CME@VindicoCME.com
View Activity
Please note you will be taken to a secondary website for the content & posttest.
